Skip to main content
. 2018 Jun 9;45(12):2122–2138. doi: 10.1007/s00259-018-4065-5

Table 5.

Prognostic impact of FDG PET: descriptive analysis

Reference Timing of FDG PET Main metabolic parameter Significant threshold/cut-off value Prognostic comparator Median follow-up (months) Primary outcome measure Main message
[18] Pretreatment MTV 14 ml ns 18 LRC, PFS 3-year LRFS and DFS lower in patients with MTV ≥14 ml
[19] Pretreatment
Interim
Posttreatment
Analysis of change over time		 SUVmax ns ns 29.2 PFS, DSS Metabolic response on posttreatment PET correlated with 2-year PFS and DSS
[20] Pretreatment MTV ns T stage, N stage, HPV status 30.5 LRC, OS PET-based nomogram: MTV as a continuous variable correlated with 2-year OS
[21] Pretreatment
Interim
Analysis of change over time		 SUVmax ns ns 23 DFS, OS SUVmax reduction ratio <0.64 associated with inferior 2-year OS and DFS
[22] Pretreatment TLG 121.9 g Uniformity (texture), HPV status 27 PFS, DSS, OS TLG >121.9 g and uniformity ≤0.138 associated with inferior PFS, DSS and OS
[23] Pretreatment MTV 40 ml ns ns DFS Worse short-term outcome and shorter DFS in patients with MTV >40 ml
[24] Pretreatment SUVmean ns ns 15 DFS SUVmean >7 (median of cohort) correlated with inferior 2-year DFS
[25] Pretreatment
Posttreatment		 SUVmax 5 Haemoglobin level 38.4 LRC, OS Posttreatment SUVmax <5 and pretreatment haemoglobin >12 g/dl correlated with superior LRC and OS
[26] Pretreatment
Posttreatment		 SUVmax 4.4 ns 52.7 PFS, OS Posttreatment SUVmax <4.4 correlated with superior 3-year PFS and OS
[27] Pretreatment MTV, uptake pattern 20 ml ns 36.4 DFS, DSS MTV >20 ml and qualitative uptake pattern (ring-shape) correlated with inferior DFS and DSS
[28] Pretreatment
Interim
Analysis of change over time		 TLG, MTV 2.95 g/ml ns 28 LRC, DFS, OS Index node SUVmean on interim PET <2.95 g/ml and TLG, MTV reduction >50% on interim PET correlated with superior LRC, DFS and OS
[29] Pretreatment
Posttreatment
Analysis of change over time		 Hopkins five-point scale ns HPV status 27 PFS, OS Hopkins five-point qualitative response interpretation and HPV status able to discriminate PFS and OS
[30] Pretreatment
Posttreatment
Analysis of change over time		 SUVmax ns ns ns LRC SUVmax reduction ratio <1.04 associated with inferior LRC
[31] Pretreatment
Interim
Posttreatment
Analysis of change over time		 Visual grading ns ns 28 LRC, DFS, OS Visual grading response interpretation able to discriminate 2-year LRC, DFS and OS
[32] Pretreatment, Interim TLG 9.4 g ns 25 LRC, DFS, OS TLG on interim PET <9.4 g correlated with superior 2-year LRC, DFS and OS
[34] Pretreatment MTV 28.7 ml T stage ns LRC, OS MTV >28.7 ml correlated with inferior 3-year LRC and OS
[35] Pretreatment
Posttreatment		 MTV ns ns 34 DFS, OS Increase in MTV2.0 (volume above SUV threshold of 2) of 21 ml associated with inferior DFS and OS
[36] Pretreatment SUVmax 19.4 kep-tumour, ve-node (MR parameters) 28 PFS, OS kep-tumour, ve-node, SUVmax independently able to discriminate 3-year PFS and OS
[37] Pretreatment MTV 18 ml Primary tumour site 40.4 LRC, OS MTV >18 ml correlated with inferior 3-year LRC and OS
[38] Pretreatment SUVmax 13 Gross tumour volume, cisplatin delivery, smoke 32 DFS, OS SUVmax <13 (median of cohort) correlated with superior DFS and OS
[39] Pretreatment MTV 9.7 ml ns 55.8 LRC, PFS, OS MTV <9.7 ml (median of cohort) correlated with superior 5-year LRC, PFS and OS
[40] Pretreatment
Posttreatment		 MTV ns ns 50 LRC, PFS Pretreatment MTV above the median correlated with inferior LRC and PFS
[42] Pretreatment
Interim
Analysis of change over time		 Hopkins five-point scale ns HPV status 20.4 PFS, OS Hopkins five-point qualitative response interpretation and HPV status able to discriminate PFS and OS
[43] Pretreatment MTV ns ns 32.5 OS MTV3.0 (volume above a SUV threshold of 3) >23.01 ml associated with inferior OS
[44] Pretreatment
Interim		 SUVmean (in MST) ns ns 29.3 LRC, OS SUVmean of MST on interim PET >2.3 g/ml (median of cohort) correlated with superior LRC and OS

ns not stated, MST mucosa and submucosa soft tissues, kep efflux rate constant of primary tumour on dynamic contrast-enhanced MR imaging, ve relative volume of extracellular extravascular space of largest metastatic lymph node on diffusion-weighted MR imaging, LRC locoregional control, PFS progression-free survival, DSS disease-specific survival, OS overall survival, DFS disease-free survival